Spero Therapeutics has secured exclusive global rights (ex-China) to develop and commercialize SP001 from Innovent Biologics, involving an upfront payment and potential milestone payments up to $1.1 billion. This agreement significantly expands Spero's pipeline with a late-stage asset targeting IgG4-RD, a condition with high unmet medical need, and positions them for a Phase 2 trial in Q2 2027.
Spero Therapeutics has entered a significant licensing agreement with Innovent Biologics, gaining exclusive global rights (excluding Greater China) to SP001. This deal involves an upfront payment to Innovent and potential milestone payments totaling up to $1.1 billion, plus tiered royalties. For Spero, this is a major pipeline expansion, adding a late-stage asset with a clear development path, as they plan to initiate a Phase 2 trial for SP001 in IgG4-related disease (IgG4-RD) in Q2 2027. Innovent benefits from substantial non-dilutive funding and retains rights for the Chinese market, where they plan a Phase 2 trial for Sjögren’s disease (SjD) by early 2027. This agreement provides a long-term growth opportunity for Spero in a market with limited therapeutic options, while Innovent monetizes its asset globally while maintaining regional control. Traders should watch SPRO for potential upside driven by this pipeline expansion and future clinical trial catalysts.